Abstract
Agitation and aggression are common neuropsychiatric symptoms of Alzheimer’s disease and are highly prevalent in people with dementia. When pharmacological intervention becomes necessary, current clinical practice guidelines recommend antipsychotics, cholinesterase inhibitors, and some antidepressants. However, those interventions have modest to low efficacy, and those with the highest demonstrated efficacy have significant safety concerns. As a result, current research is focusing on novel compounds that have different mechanisms of action and that may have a better balance of efficacy over safety. The purpose of this review is to evaluate novel pharmacological therapies for the management of agitation and aggression in AD patients. We performed a comprehensive literature search to identify recent novel drugs that are not included in most clinical practice guidelines or are currently undergoing clinical trials for the treatment of agitation and/or aggression in AD. This review suggests that novel treatments, such as cannabinoids, lithium, non-steroidal anti-inflammatory drugs, analgesics, narcotics, and newer antiepileptic drugs, may provide a safer alternative treatment option for the management of agitation and aggression in AD and requires further study in order to clarify their risks and benefits.
Keywords: Agitation, aggression, Alzheimer’s disease, analgesics, anti-inflammatory drugs, cannabinoids, lithium, narcotics.
Current Alzheimer Research
Title:Pharmacological Management of Agitation and Aggression in Alzheimer’s Disease: A Review of Current and Novel Treatments
Volume: 13 Issue: 10
Author(s): Celina S. Liu, Myuri Ruthirakuhan, Sarah A. Chau, Nathan Herrmann, André F. Carvalho and Krista L. Lanctôt
Affiliation:
Keywords: Agitation, aggression, Alzheimer’s disease, analgesics, anti-inflammatory drugs, cannabinoids, lithium, narcotics.
Abstract: Agitation and aggression are common neuropsychiatric symptoms of Alzheimer’s disease and are highly prevalent in people with dementia. When pharmacological intervention becomes necessary, current clinical practice guidelines recommend antipsychotics, cholinesterase inhibitors, and some antidepressants. However, those interventions have modest to low efficacy, and those with the highest demonstrated efficacy have significant safety concerns. As a result, current research is focusing on novel compounds that have different mechanisms of action and that may have a better balance of efficacy over safety. The purpose of this review is to evaluate novel pharmacological therapies for the management of agitation and aggression in AD patients. We performed a comprehensive literature search to identify recent novel drugs that are not included in most clinical practice guidelines or are currently undergoing clinical trials for the treatment of agitation and/or aggression in AD. This review suggests that novel treatments, such as cannabinoids, lithium, non-steroidal anti-inflammatory drugs, analgesics, narcotics, and newer antiepileptic drugs, may provide a safer alternative treatment option for the management of agitation and aggression in AD and requires further study in order to clarify their risks and benefits.
Export Options
About this article
Cite this article as:
Liu S. Celina, Ruthirakuhan Myuri, Chau A. Sarah, Herrmann Nathan, Carvalho F. André and Lanctôt L. Krista, Pharmacological Management of Agitation and Aggression in Alzheimer’s Disease: A Review of Current and Novel Treatments, Current Alzheimer Research 2016; 13 (10) . https://dx.doi.org/10.2174/1567205013666160502122933
DOI https://dx.doi.org/10.2174/1567205013666160502122933 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Aspects of Monoamine Oxidase B Inhibitors: The Key Role of Halogens to Open the Golden Door
Current Medicinal Chemistry Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets Post Mortem Redistribution of Drugs: Current State of Knowledge
Current Pharmaceutical Design Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Alzheimers Disease and Immunotherapy
Current Alzheimer Research Neurosarcoidosis
Current Neuropharmacology Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Hybrid High Exploration Particle Swarm Optimization Algorithm Improves the Prediction of the 2-Dimensional Hydrophobic-Polar Model for Protein Folding
Current Bioinformatics Enantiomeric Local Anesthetics: Can Ropivacaine and Levobupivacaine Improve Our Practice?
Current Drug Therapy Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Established and Emerging Therapies for Huntingtons Disease
Current Molecular Medicine Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin
Central Nervous System Agents in Medicinal Chemistry HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Home Oxygen Therapy for the 21st Century
Current Respiratory Medicine Reviews Multi-Nutrient Dietary Intervention Approach to the Management of Alzheimer’s Disease – A Mini-Review
Current Alzheimer Research